记者|张宝莲 编辑|程鹏魏文艺杜恒峰校对|陈柯名 历经多轮推进，杉杉集团的重整进程终于迎来新进展。 2月8日晚间，杉杉股份（SH600884，股价14.37元，市值323.24亿元）公告称，公司控股股东杉杉集团及其子公司宁波朋泽贸易有限公司（以下简称"朋泽 贸易"）、杉杉集团管理人，已与重整投资人安徽皖维集团有限责任公司（以下简称"皖维集团"）、宁波金融资产管理股份有限公司（以下简称"宁波金 资"）签署重整投资协议。 根据协议，皖维集团用于直接收购股票和按上限计算的即期出资股票的破产服务信托优先受益权的投资总额上限不超过约71.56亿元。皖维集团通过系列 安排合计控制债务人（杉杉集团及朋泽贸易）持有的21.88%杉杉股份股票的表决权或与债务人达成一致行动。若本次重整最终顺利完成，其控股股东将 变更为皖维集团，实际控制人则将变更为安徽省国资委。 图片来源：视觉中国（资料图） 皖维集团近72亿元入局 《每日经济新闻》记者（以下简称"每经记者"）注意到，杉杉股份的后续发展动态一直备受市场关注。此次安徽国资相关主体拟入局，是杉杉集团重整进 程的重要进展。 杉杉股份易主在即 公告显示，经遴选，确定皖维集团、安徽海螺集团 ...

Core Viewpoint - There has been a significant increase in control transactions among listed companies as the year-end approaches, with over 20 companies disclosing changes in control since December [1][28]. Group 1: Control Transactions - Guangxi Modern Logistics plans to acquire 14.33% of Dongfang Zhizao for 7.32 billion yuan, with the actual controller changing from Li Bin to the Guangxi State-owned Assets Supervision and Administration Commission [3][4][28]. - Jiang Pharmaceutical Group intends to acquire 8.73% of Tailong Pharmaceutical through a two-step transfer at a price of 11.04 yuan per share, totaling 5.53 billion yuan [12][33]. - Jingjiang Industrial is set to acquire 18.66% of ST Yishite for 24.37 billion yuan, with a share price of 5.61 yuan, resulting in a total valuation of 131 billion yuan [20][42]. Group 2: Financial Data of Companies - Guangxi Modern Logistics reported a revenue of 476 billion yuan in 2024, with total assets of approximately 335 billion yuan and net profit of 1.01 billion yuan [7][8][31]. - Jiang Pharmaceutical Group's revenue for 2024 was 127 billion yuan, with total assets of approximately 10.29 billion yuan and net profit of 50 million yuan for the first nine months of 2025 [18][36]. - ST Yishite's revenue was 30.44 billion yuan in 2024, with net assets of 67.83 billion yuan as of September 2025 [26][42].

Core Viewpoint - Renfu Pharmaceutical (600079.SH) is facing a fine of 17.5 million yuan due to violations associated with its former controlling shareholder, Dongdai Group, marking the end of its historical burdens and paving the way for a "third entrepreneurship" under the control of China Merchants Group [2] Group 1: Company Developments - Renfu Pharmaceutical's stock will be suspended for one day on December 15, 2025, and will be subject to risk warnings starting December 16, 2025, with its A-share name changing to "ST Renfu" [2] - The company reported a revenue of 17.883 billion yuan and a net profit attributable to shareholders of 1.1 billion yuan, marking a year-on-year increase of 6.22%, ending a two-year decline [7] - The company has successfully rectified the violations mentioned in the administrative penalty notice, ensuring that future operations will not be affected [7] Group 2: Industry Context - Dongdai Group, once the largest private enterprise group in Hubei, controlled four A-share listed companies and had total assets exceeding 100 billion yuan before facing a debt crisis [4] - The debt crisis led to the transfer of control of its listed companies to state-owned enterprises, with significant changes in management and operational performance observed post-acquisition [5][6] - Other companies under Dongdai Group, such as Santai Cableway and ST Mingcheng, have shown remarkable recovery in performance after the change in control, with Santai Cableway achieving a revenue increase of 180.67% in 2023 [3][8]